Ymmunobio

We are very proud to announce our 3rd place achievement at the Prix Galien USA Awards! 🏆 Honored to be nominated, and thrilled to secure 3rd place at this prestigious event! Although typically only the winner is announced, a Prix Galien Foundation team member remembered Ymmunobio because of our unique name and that “Y” in front—it sparked a conversation and a smile! The evening was an incredible blend of inspiration and connection. We met trailblazers across pharma, biotech, med tech, AI, and more, each pushing boundaries in their fields. The gala was hosted in the breathtaking American Museum of Natural History in NYC, surrounded by stunning exhibits (including a towering dinosaur skeleton!). A big thank you to everyone who helped make this night memorable, and here’s to many more innovative milestones ahead! #PrixGalien #LifeSciences #Innovation #Biotech #Pharma #MedTech #HealthcareInnovation #Networking #MuseumOfNaturalHistory #ProudMoment #Ymmunobio

🚀 Pioneering Transformative Therapy Solutions for Patients! 🚀 Ymmunobio in collaboration with the PSI Paul Scherrer Institute, has been awarded an Innosuisse innovation grant to develop innovative radioactive-loaded antibodies for the treatment and diagnostic of solid tumors based on Ymmunobio's proprietary YB-800. The Innosuisse support validates Ymmunobio’s approach to targeted solid tumor therapy using a new and first-in-class target with a high prevalence in cancer patients. The newly developed antibodies will utilize a linker attached to YB-800, capable of carrying any radioactive isotope to treat and diagnose solid tumors. Ymmunobio plans to leverage this cutting-edge technology to treat patients with solid tumors who express the new marker. Radiolabeled antibodies will enhance physicians' ability to diagnose using SPECT imaging while simultaneously targeting solid tumors that evade current therapies, paving the way for more personalized and effective treatment strategies. Together, Ymmunobio and PSI Paul Scherrer Institute are pioneering advances in diagnostics and treatments in oncology, working towards a future where healthcare is more personalized, precise, and effective for all patients.

Such exciting news! Very proud to be able to support Ymmunobio on their journey and I cannot wait to hear the outcome! Fingers crossed!

🚀 Countdown to the Prix Galien Awards: Showcasing Science-Driven Innovation in NYC! 🚀 In just two weeks Ymmunobio is heading to New York for the prestigious Prix Galien USA Awards, where we'll be competing in the "Best Startup" category! It’s an incredible honor to be recognized by such an esteemed foundation that celebrates innovation and excellence in life sciences and healthcare. The Prix Galien, often called the "Nobel Prize of pharmaceutical and medical innovation," acknowledges groundbreaking work in biotechnology, diagnostics, digital health, and more. Being among so many inspiring companies, innovators, and thought leaders who are shaping the future of healthcare is truly humbling.   We’re excited to showcase our work, connect with others who are just as passionate about transforming patient outcomes, and bring our vision one step closer to reality. We want to extend a huge thanks to our dedicated team, supporters, and partners who have helped us get here – your commitment drives our success!   We will keep you posted!  #prixgalienusa

🚀 Farewell and Best Wishes to Angela S. Gibbs 🎉 Today, we are sad to say goodbye to a truly remarkable team member. Angela has been invaluable to our leadership team, bringing dedication, innovation, and a positive attitude to Ymmunbio, the team, and all our stakeholders. Over the past 18 months, Angela has played a critical role in driving the Ymmunobio mission forward! Angela has done a spectacular job bringing the groundbreaking work that Ymmunobio is performing to revolutionize cancer care closer to future investors and collaborators. Angela’s passion for people, drive for success and strategic and focused thinking has really supported the leadership team to align on key milestones and grow its visibility in the biotech space. While we are sad to see Angela go, we are also excited for her to embark on a new journey. We do not doubt that she will continue to shine and accomplish great things. Please join me in wishing Angela all the best in her future endeavors. Stay in touch and keep us posted on your adventures ahead. You'll always be a part of the Ymmunobio family! #Farewell #NewBeginnings #BestWishes #ThankYou

We are very excited about our collaboration with EVIIVE. Not only for developing a liquid biopsy companion diagnostic for our cancer treatments, but also in the long run developing a potential standard diagnostic for early detection of solid tumors.

🚀 Exciting Collaboration Announcement! 🚀 We are thrilled to announce a groundbreaking partnership between Ymmunobio and EVIIVE to advance the future of cancer diagnostics! Together, we are developing an innovative liquid biopsy technology using extracellular vesicles (EVs), enhancing precision in disease detection and monitoring Our joint efforts will leverage Ymmunobio 's cutting-edge biotechnological expertise and EVIIVE's advanced diagnostic platforms to create a revolutionary tool in the fight against cancer. Ymmunobio and EVIIVE are pioneering advances in diagnostics and oncology, working towards a future where healthcare is more personalized, precise, and effective for all patients. Stay tuned for more updates as we work towards a brighter, healthier future! #CancerResearch #Biotech #LiquidBiopsy #InnovationInHealthcare #Ymmunobio #EVIIVE #CancerDetection #HealthcareInnovation #CollaborationForCure https://lnkd.in/dBK-vrvM

🚀 Ymmunobio is proud to announce our ASCO Publication on YB800! 🚀 Ymmunobio 's abstract entitled: “YB-800, a monoclonal antibody targeting the human neuronal pentraxin receptor (NPTXR), as a potential candidate for the design of a first-in-class antibody-drug conjugate (ADC) as a novel therapeutic intervention in gastro-intestinal cancers” has been published in the American Society of Clinical Oncology (ASCO) annual conference proceedings. The full publication can be found here: https://lnkd.in/ex-wVePZ The abstract highlights using a fully humanized monoclonal antibody (YB-800) directed against the human neuronal pentraxin receptor (NPTXR). The expression of NPTXR has been associated with disease progression in several GI cancers, including gastric, esophageal, colorectal, pancreatic, bladder, and liver, as well as breast and thyroid cancer. These findings provided a strong rationale for the design of a YB-800-based ADC, offering a novel therapeutic intervention option for patients with high unmet medical needs. We are thrilled to contribute to the advancement of cancer treatment and are dedicated to pursuing innovative therapies that can significantly impact patient care. ********************************************************************************* #ASCO #Ymmunobio #CancerResearch #MonoclonalAntibodies #GICancer #InnovativeTherapies #Oncology #ADC #MedicalResearch #HealthcareInnovation

🌟 Ymmunobio on tour! 🌟 We are thrilled to announce that Ymmunobio is currently on tour in Boston, with the Venturelab leaders and the innovative Swiss Biotech Association Team. This is an incredible opportunity for us to engage with some of the brightest minds in the biotech industry, exchange groundbreaking ideas, and explore new avenues for collaboration and growth. A big thank you to Venturelab for this unique opportunity and to the Swiss Biotech Association Team for their unwavering support. We are confident that this experience will be a significant milestone in our mission to revolutionize the biotech landscape. Stay tuned for updates from our Boston adventure! 🚀 #Ymmumbio #Venturelab #SwissBiotechTeam #BiotechInnovation #VLeadersBiotech #SwissStartups https://lnkd.in/euNngaxD

"We are dedicated to establishing proof of concept with our ADC targeting NPXTR!" Global Business Reports (GBR) interviews our CEO & Co-Founder Peter Schiemann who shares the latest Ymmunobio developments and key focus areas for 2024. You can read the full interview here: https://lnkd.in/eVcgaMJK